gvtcx

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

NHS England Published 27 Feb 2018 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£72,000,000
Statuscomplete
Category (CPV) 33600000
RegionScotland, Wales, Northern Ireland
Deadline29 Mar 2018
Contract start1 Jul 2018
Contract end30 Jun 2019
Procedureopen
SME suitableYes
OCIDocds-b5fd17-1d6a380a-446a-4d72-ac49-db35a20e38a5

Awards (3)

This procurement was awarded to 3 suppliers. Values shown are per-award; the notice total is £72,000,000.

SupplierValueDateStatus
CSL Behring UK Limited shared £72,000,000 19 Jun 2018 active
Pharming Technologies NV shared £72,000,000 19 Jun 2018 active
Shire Pharmaceuticals Ltd shared £72,000,000 19 Jun 2018 active

description

NHS Framework Agreement for the supply of Icatibant and C1-Esterase products for the treatment of Hereditary Angioedema. The framework will commence on 1st July 2018 for a period of 12 months until 30th June 2019, with options to extend up to a further 36 months.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
16 Jul 2018 Award (award) · 7400eba6-8e62-4241-879e-a0c574ef4408-229021

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.